These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 29943453

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients.
    Tetzlaff MT, Nelson KC, Diab A, Staerkel GA, Nagarajan P, Torres-Cabala CA, Chasen BA, Wargo JA, Prieto VG, Amaria RN, Curry JL.
    J Immunother Cancer; 2018 Feb 12; 6(1):14. PubMed ID: 29433571
    [Abstract] [Full Text] [Related]

  • 3. Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features.
    Tetzlaff MT, Nagarajan P, Chon S, Huen A, Diab A, Omar P, Aung PP, Torres-Cabala CA, Mays SR, Prieto VG, Curry JL.
    Am J Dermatopathol; 2017 Feb 12; 39(2):121-129. PubMed ID: 28134729
    [Abstract] [Full Text] [Related]

  • 4. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V.
    Am J Clin Dermatol; 2018 Jun 12; 19(3):345-361. PubMed ID: 29256113
    [Abstract] [Full Text] [Related]

  • 5. PD-1 inhibitor-associated lichenoid inflammation with incidental suprabasilar acantholysis or vesiculation-Report of 4 cases.
    Chou S, Zhao C, Hwang SJE, Fernandez-Penas P.
    J Cutan Pathol; 2017 Oct 12; 44(10):851-856. PubMed ID: 28753231
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.
    Ellis SR, Vierra AT, Millsop JW, Lacouture ME, Kiuru M.
    J Am Acad Dermatol; 2020 Oct 12; 83(4):1130-1143. PubMed ID: 32360716
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
    Shao K, McGettigan S, Elenitsas R, Chu EY.
    J Cutan Pathol; 2018 Jan 12; 45(1):74-77. PubMed ID: 29028121
    [Abstract] [Full Text] [Related]

  • 11. Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern.
    Trinidad C, Nelson KC, Glitza Oliva IC, Torres-Cabala CA, Nagarajan P, Tetzlaff MT, Ivan D, Hwu WJ, Prieto VG, Curry JL, Aung PP.
    J Cutan Pathol; 2018 Jul 12; 45(7):504-507. PubMed ID: 29633300
    [Abstract] [Full Text] [Related]

  • 12. Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immune-related adverse event with mycosis-fungoides-like morphologic and molecular features.
    Tetzlaff MT, Tang S, Duke T, Grabell DA, Cabanillas ME, Zuo Z, Yao JC, Nagarajan P, Aung PP, Torres-Cabala CA, Duvic M, Prieto VG, Huen A, Curry JL.
    J Cutan Pathol; 2019 Nov 12; 46(11):872-877. PubMed ID: 31254410
    [Abstract] [Full Text] [Related]

  • 13. Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma.
    Mochel MC, Ming ME, Imadojemu S, Gangadhar TC, Schuchter LM, Elenitsas R, Payne AS, Chu EY.
    J Cutan Pathol; 2016 Sep 12; 43(9):787-91. PubMed ID: 27161449
    [Abstract] [Full Text] [Related]

  • 14. [Dermatologic toxicities of immune checkpoint inhibitors].
    Sibaud V, Boulinguez S, Pagès C, Riffaud L, Lamant L, Chira C, Boyrie S, Vigarios E, Tournier E, Meyer N.
    Ann Dermatol Venereol; 2018 May 12; 145(5):313-330. PubMed ID: 29678394
    [Abstract] [Full Text] [Related]

  • 15. The diverse landscape of dermatologic toxicities of non-immune checkpoint inhibitor monoclonal antibody-based cancer therapy.
    Seervai RNH, Friske SK, Chu EY, Phillips R, Nelson KC, Huen A, Cho WC, Aung PP, Torres-Cabala CA, Prieto VG, Curry JL.
    J Cutan Pathol; 2023 Jan 12; 50(1):72-95. PubMed ID: 36069496
    [Abstract] [Full Text] [Related]

  • 16. Ipilimumab-associated halo-like inflammatory reactions around nevi during therapy for metastatic melanoma.
    Alniemi DT, Fischer A, Greene LA, Pierson JC.
    Dermatol Online J; 2018 Jul 15; 24(7):. PubMed ID: 30261564
    [Abstract] [Full Text] [Related]

  • 17. Distinguishing histopathologic features of acantholytic dermatoses and the pattern of acantholytic hypergranulosis.
    See SHC, Peternel S, Adams D, North JP.
    J Cutan Pathol; 2019 Jan 15; 46(1):6-15. PubMed ID: 30203619
    [Abstract] [Full Text] [Related]

  • 18. Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study.
    Kawsar A, Edwards C, Patel P, Heywood RM, Gupta A, Mann J, Harland C, Heelan K, Larkin J, Lorigan P, Harwood CA, Matin RN, Fearfield L.
    Br J Dermatol; 2022 Dec 15; 187(6):981-987. PubMed ID: 35976170
    [Abstract] [Full Text] [Related]

  • 19. Granulomatous Tumoral Melanosis Associated With Pembrolizumab Therapy: A Mimicker of Disease Progression in Metastatic Melanoma.
    Woodbeck R, Metelitsa AI, Naert KA.
    Am J Dermatopathol; 2018 Jul 15; 40(7):523-526. PubMed ID: 29924748
    [Abstract] [Full Text] [Related]

  • 20. [Acantholytic dermatosis in patients treated by vemurafenib: 2 cases].
    Sabatier-Vincent M, Charles J, Pinel N, Challende I, Claeys A, Leccia MT.
    Ann Dermatol Venereol; 2014 Nov 15; 141(11):689-93. PubMed ID: 25442474
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.